Skip to main content
PeerJ logoLink to PeerJ
. 2024 Jul 18;12:e17643. doi: 10.7717/peerj.17643

A multi-ethnic proteomic profiling analysis in Alzheimer’s disease identifies the disparities in dysregulation of proteins and pathogenesis

Mei Sze Tan 1, Phaik-Leng Cheah 2, Ai-Vyrn Chin 3, Lai-Meng Looi 2, Siow-Wee Chang 1,4,
Editor: Vladimir Uversky
PMCID: PMC11260413  PMID: 39035156

Abstract

Background

Alzheimer’s disease (AD) is the most common type of dementia that affects the elderly population. Lately, blood-based proteomics have been intensively sought in the discovery of AD biomarkers studies due to the capability to link external environmental factors with the development of AD. Demographic differences have been shown to affect the expression of the proteins in different populations which play a vital role in the degeneration of cognitive function.

Method

In this study, a proteomic study focused on Malaysian Chinese and Malay prospects was conducted. Differentially expressed proteins (DEPs) in AD patients and normal controls for Chinese and Malays were identified. Functional enrichment analysis was conducted to further interpret the biological functions and pathways of the DEPs. In addition, a survey investigating behavioural practices among Chinese and Malay participants was conducted to support the results from the proteomic analysis.

Result

The variation of dysregulated proteins identified in Chinese and Malay samples suggested the disparities of pathways involved in this pathological condition for each respective ethnicity. Functional enrichment analysis supported this assumption in understanding the protein-protein interactions of the identified protein signatures and indicate that differentially expressed proteins identified from the Chinese group were significantly enriched with the functional terms related to Aβ/tau protein-related processes, oxidative stress and inflammation whereas neuroinflammation was associated with the Malay group. Besides that, a significant difference in sweet drinks/food intake habits between these two groups implies a relationship between sugar levels and the dysregulation of protein APOA4 in the Malay group. Additional meta-analysis further supported the dysregulation of proteins TF, AHSG, A1BG, APOA4 and C4A among AD groups.

Conclusion

These findings serve as a preliminary understanding in the molecular and demographic studies of AD in a multi-ethnic population.

Keywords: Alzheimer’s disease (AD), Blood-biomarkers, Multi-ethnics, Proteomics, Dysregulated proteins

Introduction

Alzheimer’s disease (AD) is the most common type of dementia, an age-related neurodegenerative disease characterized by unusual changes in the brain which subsequently cause devolution in behaviour, thinking, memory and ability to carry out daily tasks (Tan et al., 2021). Several risk factors are reported to be associated with AD, such as age, hereditary and family history (Alzheimer’s Association, 2020; Mucke, 2009). Several proteins are known to be associated with the initiation and development of AD, including β-amyloid (), tau-protein, amyloid precursor protein (APP) and ε4 allele of apolipoprotein E (ApoE4). Although numerous studies have been performed to explain AD’s aetiology, most of the findings were related to plaque and tau tangle deposition in the brain. The altered and causative mechanism, together with the chemical and molecular components that lead to AD pathology remain unclear.

Currently, the clinical diagnosis of AD mainly depends on a series of examinations based on neurophysiological assessments of the patient’s cognitive function (Daffner, 2000; Yao et al., 2019). A variety of techniques have been widely used recently to support the diagnosis of AD such as neuroimaging techniques e.g., positron emission tomography (PET) and neurochemical assay testing in the cerebrospinal fluid (CSF) and blood (Shen et al., 2017). As blood is more accessible than CSF, the investigation of blood-based biomarkers is gaining traction in AD studies lately, as an alternative to CSF and PET examinations that are rather invasive or high in price (Zetterberg & Burnham, 2019). Several evaluations have been done using blood-based biomarkers in AD, but the results have been inconsistent (Janelidze et al., 2016; Rehiman et al., 2020a, 2020b; Yao et al., 2019). Such inconsistencies observed in Aβ, APP and ApoE4 could be due to their low concentrations in blood compared with CSF as well as the variations in the methods used (Zetterberg & Burnham, 2019). Nevertheless, we feel blood for assay of biomarkers, due to its easy accessibility, will remain an important candidate for studying AD, and hence our interest in developing along this line, with augmentation of standardised technical methods by advanced bioinformatics.

Large-scale genomic and transcriptomic studies have been carried out to uncover the disease pathological networks and their related novel therapeutic markers (Jansen et al., 2019; Patel, Dobson & Newhouse, 2019; Su et al., 2019; Wightman et al., 2020); however, these have not been able to significantly indicate the functional gene products i.e., proteins (Bai et al., 2020; Liu, Beyer & Aebersold, 2016). On the other hand, the set of involved proteins, known as proteomes, is more dynamic than what can be captured by genomics and transcriptomics, as protein expressions are often influenced by external environmental factors (International Service for the Acquisition of Agri-biotech Applications, 2006). The identification of aberrant protein expressions that affect the pathogenesis of AD should still be the main goal in studying the perturbation of processes related to AD (Madrid et al., 2021; Shen et al., 2017; Zahid et al., 2014). With the advancement in technology, for example, by using mass spectrometry (MS), there can be in-depth profiling and quantification of proteins in biological samples. The relatively high resolution of MS technology has replaced the application of the low resolution and time-consuming two-dimensional gel electrophoresis (2-DE) in measuring protein information, especially in complex diseases (Tan et al., 2021). Computational methods to analyse a large number of extracted proteins have been crucial to provide further insight.

There are many factors involved in affecting the regulation of proteins, such as genetic regulation, genetic coding and external environmental factors (Wu et al., 2021). Among these factors, the correlation between the environmental factors (i.e., living environment, lifestyle practices and dietary plans) with the dysregulation of proteins in AD is the main interest of this study.

Malaysia has a multi-ethnic population that comprises Malays (69.6%), Chinese (22.6%), Indians (6.8%) and other races (1.0%) (Department of Statistics Malaysia, 2021). In the same year, people ≥65 years of age formed about 7.4% of the total 32.7 million Malaysian population (Department of Statistics Malaysia, 2021). It is also expected that Malaysians who are diagnosed with dementia will reach 261,000 in the year 2030 according to a report published by the Alzheimer’s Disease International in year 2015, and this number can rise with the increase in lifespan (Alzheimer’s Disease International et al., 2015). The multiethnicity and its concomitant rich variety of cultural practices among the various races can provide insights into AD with regard to biological and environmental influences.

We conducted an unbiased proteomic analysis using AD patients and normal controls to investigate the disease-associated blood proteome changes in the two major ethnic groups in Malaysia namely the Chinese and Malay. To the best of our knowledge, this study is the first study conducted in Malaysia to compare the blood proteomic profiles between the Chinese and Malay ethnics. The pathways associated with AD and the interactions between the differentiated proteins in these two groups were the main interest of this study. The proteins were profiled using quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) based on TMT labelling. Differential expression analysis was performed to identify significant proteins with aberrant abundance. Functional and network analyses were conducted next to identify the protein-protein interactions and pathways of the dysregulated proteins in the two different races. Furthermore, a survey was conducted to compare the sociodemographic characteristics, lifestyle, dietary and behavioural practices of the Chinese and Malay patients. This survey aimed to provide supportive evidence on the possible correlation between external environmental factors to which the two ethnic groups have been subjected and any identified dysregulated proteins. To increase the statistical power and reliability of the findings, a meta-analysis was performed for the identified dysregulated proteins.

Materials and Methods

The proposed pipeline is illustrated in Fig. 1.

Figure 1. Pipeline for the comparison of AD-associated blood proteome changes in Chinese and Malay Malaysians.

Figure 1

Subjects

A total of 12 subjects, eight patients diagnosed with AD, and four normal controls, were recruited from the Memory and Geriatric clinics at the Universiti Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia respectively. Written informed consent (BK-MIS-1117-E01) was obtained from all subjects involved in the study. The 12 subjects comprised five AD patients and two normal controls in the Chinese group and three AD patients and two normal controls in the Malay group. All subjects are Malaysian citizens and ≥65 years of age at the time when they were recruited in this study. The selection of AD patients was made based on the criteria stated in Table 1.

Table 1. Inclusion and exclusion criteria of selecting AD patients and normal controls.

Subject Inclusion criteria Exclusion criteria
AD Malaysian Under palliative care for other diseases
65 years old and above Diagnosed with other type of dementia such as: vascular dementia; lewy body dementia; Parkinson’s disease dementia; frontotemporal dementia; creutzfeldt-Jakob disease; wernicke-korsakoff syndrome; normal pressure hydrocephalus; Huntington’s disease; down-syndrome dementia.
Shows symptoms of memory deterioration which have worsened with time
Show symptoms of losing the ability to perform daily function
Diagnosed with AD for more than 2 months
Normal controls Malaysian Patients under palliative care for other diseases
65 years old and above Diagnosed with AD/any other type of dementia.
Does not show symptoms of memory deterioration Diagnosed with a known significant (in the view of the investigator) concurrent medical disease.
Able to perform daily function

At the same time, each AD subject was provided with a questionnaire which included sociodemographic details, dietary habits and other behavioural practices. The answers supplied by the subjects were corroborated by the accompanying caregiver.

The above study was approved by the Universiti Malaya Medical Centre (UMMC) Medical Research Ethics Committee with the approval number of 2020114-9193.

Sample processing

A total of 10 ml of blood was collected from each subject in the BD Vacutainer CAT blood collection tubes and were centrifuged at 1,000 g for 10 min at room temperature. The serum supernatant was collected, centrifuged at 2,500 g for 10 mins at room temperature and then stored at −80 °C until further processing.

Sample preparation

Depletion of high-abundance proteins was performed on all 12 serum samples using ITSIPREP Albumin Segregation Kit-Solvent (ASKs) (ITSI Bioscience, Johnstown, PA, USA) according to the protocol outlined by the manufacturer. The samples were then pooled according to the race and gender of the subjects, as in Table 2. The protein concentration of the eight pooled samples was determined using the Biorad Bradford Assay Kit (Biorad, Hercules, CA, USA). Sample digestion was carried out according to the manufacturer’s instructions. Following digestion, peptides were eluted from the column, dried by vacuum centrifugation and reconstituted in 200 mM HEPES (pH 8.8), with the peptide concentration subjected to Pierce quantitative colourimetric peptide assay (Thermo Scientific, Waltham, MA, USA).

Table 2. List of sample details and the corresponding TMT tags.

Sample pool Label Patient/control Race Gender Age* Education background
AD1 126 Patient 1 Chinese Female 75 Tertiary
Patient 2 Chinese Female 74 Secondary
Patient 3 Chinese Female 75 No formal
AD2 127N Patient 4 Chinese Male 70 Tertiary
Patient 5 Chinese Male 75 Tertiary
AD3 127C Patient 6 Malay Female 86 Tertiary
AD4 128N Patient 7 Malay Male 84 Secondary
Patient 8 Malay Male 75 Tertiary
AD5@ 130C Patient 4 Chinese Male 70 Tertiary
Patient 5 Chinese Male 75 Tertiary
Ctrl1 128C Control 1 Chinese Female 84 Primary
Ctrl2 129N Control 2 Chinese Male 73 Tertiary
Ctrl3 129C Control 3 Malay Female 78 Secondary
Ctrl4 130N Control 4 Malay Male 74 Tertiary
Ctrl5@ 131 Control 2 Chinese Male 73 Tertiary

Notes:

*

Age of subjects at the year of recruitment.

@

Technical replicates that are used as standard in controlling variation.

TMT-labelling and data-dependent acquisition LC-MS/MS

The eight pooled samples and two technical replicates were labelled in a 10-plex TMT label batch as indicated in Table 2. The labelling of the TMT reagent (Thermo Scientific, Waltham, MA, USA) for each sample was according to the Australian Proteome Analysis Facility (APAF) SOP MS-096. The pooled peptide mixture was then separated into three fractions using Pierce High pH reverse phase centrifugal columns. HpH fractionated TMT-labelled peptides were subjected to LC-MS/MS analysis. The instrument was operating in positive ion mode, scanning peptide precursors from 350 to 1,850 m/z at 60 k resolution. The ten peptide ions that showed the most intense signals in the survey scan were fragmented by HCD using a normalized collision energy of 33 with a precursor isolation width of 0.8 m/z.

Protein identification and quantification

The raw data were processed using Proteome Discoverer (Version 2.1.0.81, Thermo Scientific, Waltham, MA, USA). The data were searched using search engines SequestHT and Mascot against a sequence database for the Homo sapiens. The parameters for the data processing are shown in Supplemental Methods. The raw quantitative data were used for further bioinformatics analysis.

Bioinformatics data analysis

A scale normalization was applied and the data were log-2 transformed according to median of all samples before the bioinformatics analysis. Visualization of the protein abundances was carried out in the first step using principal component analysis (PCA) and hierarchical clustering (HC) to explore the patterns of similarity between the two ethnic samples.

Next, two comparison groups were made throughout the analysis: (i) Chinese AD vs Chinese Control (CADvC) and (ii) Malay AD vs Malay Control (MADvC). Firstly, differential protein analysis was performed which was followed by HC to identify aberrant proteins as well as to investigate the variation of protein abundances among the two racial groups. Next, protein-protein interaction (PPI) network and functional enrichment analysis were carried out to understand the functional roles and pathways involved by the identified correlated proteins in AD pathogenesis.

Differential protein analysis

Differential protein analysis was carried out in this study using the Linear Models for Microarray Analysis (LIMMA) package, Bioconductor R, to find out the differentially expressed proteins (DEPs). Proteins with an adjusted p-value of <0.05 were selected and ranked as the top DEPs. Benjamini and Hochberg’s (BH) method was used as the adjusting method to control the proportion of the false discovery rate within 5% of the total genes. The upregulated and downregulated proteins were grouped according to the marking value of LogFC > 0 and logFC < 0, respectively.

Hierarchical clustering

Unsupervised HC was performed to identify differentially expressed proteins across the two comparison groups. HC was also carried out using the entire proteomic dataset to observe the expression patterns of proteins from different ethnic groups, as mentioned in the earlier step. Pearson correlation coefficient was applied in this step to obtain the clusters of correlated proteins.

Functional enrichment and protein-protein interaction network analysis

STRING (version 11.5) (Szklarczyk et al., 2019) was used to construct the protein-protein interaction (PPI) networks of the identified DEPs. An interaction score of >0.4 was set to allow protein interactions with medium confidence to be constructed in the networks. Functional enrichment of the interacted proteins identified through PPI networks was computed using the ClueGO application in Cytoscape (Bindea et al., 2009). The default background corresponding to the genome-wide genes of Homo sapiens was selected. Gene Ontology (GO) terms including biological process, molecular functions and cellular functions were selected. KEGG pathways involved by the interacted proteins were also investigated. A two-sided hypergeometric test with Bonferonni step-down was applied to calculate the p-value correction of each term and the network connectivity (Kappa, Turin, Italy) score was set to 0.4. Pathways with p-value <0.05 were considered significantly enriched.

Data analysis on sociodemographic, lifestyle and physical survey of the participants

Statistical analysis was performed on the survey data collected from the 12 subjects to find out the relationship between sociodemographic characteristics, practices of lifestyle, dietary and other behavioural activities with AD among different ethnicities. Scores were given to each question according to their minimum frequency/amount measured daily, weekly or at one time, depending on their characteristics. Several questions were grouped according to their characteristics and average scores of the group measurement were calculated to reduce the complexity and enhance the normality of the data. In total, 28 variables were used to assess the relationship with the ethnic groups. The nonparametric test of Mann-Whitney U test (p-value < 0.05) was used to analyse the continuous variables while Fisher exact test (p-value < 0.05) was used for the categorical variables. This is due to the ability of nonparametric methods to tolerate small-size samples and the assumption of data normality is void. The statistical tests were conducted to check whether there are significant differences between the two groups (Chinese and Malay) on the sociodemographic characteristics, practices of lifestyle, dietary and other behavioural activities.

Next, the Pearson correlation coefficient was carried out to find out the correlation of the variables with AD status, in each ethnic group. This test was conducted on the variables that showed significant differences between the Chinese and Malay groups. In this study, a 95% confidence interval was applied, with a p-value < 0.05 considered to be significant.

Meta-analysis

Meta-analysis was performed on the significant DEPs with the relative abundances mean and standard deviation (SD) using Meta-essentials, version 1.5 (Suurmond, van Rhee & Hak, 2017). Systematic literature was searched through the database of PubMed based on keywords of “Alzheimer’s Disease”, “proteomics”, “biomarkers” and “human”. Studies that reported the mean and SD of the selected dysregulated protein candidates for CADvC (VDBP, TF, LTF, AHSG, F9, SELENOP, RBP4, ECM1, ITIH1, HGFAC, A1BG, KRT1 and KRT10) and MADvC (APOA4, FGA, C2, C4A and ITIH4) were included. For studies that did not provide relevant information, corresponding authors were contacted through email. Meta-analysis was performed for the DEPs that were reported in at least two studies. The outcomes were presented in the standardized mean differences (SMD) of AD and normal control group, measured using Hedges’ algorithm. A confidence interval (CI) of 95% was applied in this study. As variations occurred in the biomarker measurement of different studies (e.g., different proteomic platforms), a random effect model was used. The heterogeneity of the included studies was assessed using Cochran’s Q test, t-statistic and I2 index.

Results

The TMT quantitative proteomic analysis of the serum samples in our study resulted in the identification and quantification of 172 unique proteins. Pre-processing methods were performed on the data, such as the exclusion of the identified highly-abundance serum albumin proteins and proteins with missing values prior to the subsequent downstream analysis. As a result, 163 proteins were included in the analysis.

Differential protein expression analysis

To observe the cluster conditions of the samples, unsupervised clustering was carried out using PCA and HC. PCA result showed the samples were clustered by ethnicities, as illustrated in Fig. 2A while Fig. 2B shows the HC conducted based on the top 10% of the proteins with the highest variance across the samples. The full version of HC using 163 proteins is attached in Fig. S1. Similarly to the result of PCA, the hierarchical tree clearly indicated the clusters of samples by the two ethnicities. Nevertheless, as the proteins do not perform differential expression analysis yet, the clusters identified are less distinguishable in terms of AD vs control.

Figure 2. Visualisation of the samples’ clusters using (A) PCA and (B) HC.

Figure 2

Differential expression analysis of the quantitative proteomics data (n = 163) was performed using LIMMA (adjusted p-value < 0.05) across the two comparison groups: CADvC and MADvC. Significant dysregulated proteins identified from each comparison group were listed in Table 3. A Venn diagram of the identified DEPs from the two comparison groups is shown in Fig. 3A. From this finding, it can be observed that most of the DEPs identified in CADvC did not overlap with the DEPs identified in MADvC. Only one protein, F12, was noted in both ethnic groups, and appeared to be upregulated in CADvC but downregulated in MADvC. These suggested that the protein abundances in ethnic groups of Chinese and Malay AD patients might be different.

Table 3. List of differentially expressed proteins (DEPs) identified through LIMMA in the two comparison groups: CADvC and MADvC.

Chinese AD vs Chinese control (CADvC)
Accession Protein name logFC adj.P.Val Regulation
Chinese AD vs Chinese control (CADvC)
A0A286YFJ8 IGHG4 0.9111454 0.0026895 Up
P00748 F12 0.790919 0.0043438 Up
P04264 KRT1 0.773537 0.0047613 Up
Q92496 CFHR4 0.9942576 0.0072636 Up
P35527 KRT9 0.6347817 0.009087 Up
Q04756 HGFAC 0.7197487 0.0119676 Up
P13645 KRT10 0.7481082 0.0155827 Up
P36980 CFHR2 1.0779595 0.0222128 Up
P02765 AHSG 0.5314173 0.0237169 Up
P02753 RBP4 0.9520529 0.026608 Up
Q5SQ11 PTGDS 0.647988 0.0284087 Up
P02774-3 VDBP 0.8069054 0.0287951 Up
P49908 SELENOP 0.5142812 0.0298058 Up
P04217 A1BG 0.5457707 0.0352925 Up
A6NC48 BST1 0.5960251 0.0361826 Up
P02787 TF 0.6400018 0.0372747 Up
P02788 LTF 0.7742431 0.0396698 Up
Q16610-4 ECM1 0.6953304 0.0414427 Up
P00740 F9 0.4752045 0.0212655 Up
A0A096LPE2 SAA2-SAA4 −0.7740782 0.0128821 Down
P02042 HBD −1.2352253 0.0131224 Down
O75882 ATRN −0.5770248 0.014957 Down
P19827 ITIH1 −0.910063 0.0184665 Down
A0A0C4DH31 IGHV1-18 −1.6953243 0.0283833 Down
A0A087WSY6 IGKV3D-15 −1.1552825 0.0286905 Down
A0A0G2JMB2 IGHA2 −0.8217308 0.0420321 Down
Malay AD vs Malay control (MADvC)
P02671 FGA 1.1257808 0.0078898 Up
A0A087WSY6 IGKV3D-15 0.5932666 0.0413459 Up
A0A0G2JPR0 C4A −1.0490485 0.0037218 Down
P06681 C2 −0.9597209 0.0065765 Down
Q12805 EFEMP1 −0.8564646 0.0090733 Down
Q14624 ITIH4 −0.8005078 0.0122691 Down
P00748 F12 −0.7457226 0.015647 Down
A0A286YEY4 IGHG2 −0.7778262 0.0193615 Down
P06727 APOA4 −1.1521863 0.0213486 Down
P13646 KRT13 −1.1226734 0.0283367 Down
P35908 KRT2 −0.870911 0.0427892 Down
P18065 IGFBP2 −0.7772892 0.0440745 Down

Figure 3. Differential abundance of proteins observed in AD.

Figure 3

(A) Venn diagram of the identified DEPs from the two comparison groups: CADvC and MADvC. (B) Hierarchical clustering of 27 DEPs obtained from comparison group CADvC using LIMMA. (C) Hierarchical clustering of 10 DEPs obtained from comparison group MADvC using LIMMA.

Figure 3A shows the Venn diagram of the identified DEPs from CADvC and MADvC. HC was again carried out independently with the DEPs identified from each of the respective comparison groups (Figs. 3B and 3C). The resulting heatmaps segregated the AD and control cases in Chinese and Malays, as shown in Figs. 3B and 3C. This verified that the identified DEPs were significantly in distinguishing between AD cases and controls according to the respective race and supported that selected DEPs could be potential markers for AD in Chinese and Malays, respectively.

PPI network analysis

Following this, PPI was constructed to enhance the understanding of the role and interaction of the correlated dysregulated proteins using the identified DEPs. The PPI networks of correlated proteins identified in CADvC and MADvC (Table 3) are illustrated in Fig. 4.

Figure 4. Protein-protein interaction networks of the correlated proteins identified in (A) CADvC, (B) MADvC.

Figure 4

The proteins are represented by the coloured nodes and are joined by the edges that represent the protein-protein interactions where the joint proteins commonly contribute to some shared functions/roles.

From the findings illustrated in Fig. 4, it can be seen that all the proteins of immunoglobulin heavy chains were not found in the STRING database. Hence, they were excluded from the PPI networks in this study. This might be due to their nature as part of the polypeptide subunit of an antibody which was not recognised as a complete protein. PPI demonstrated the possibility of one/a group of proteins which affected the expression of other proteins in the regulation i.e., the activation/inhibition of certain pathways. Figure 4A demonstrated the interaction of proteins AHSG, SELENOP, RBP4, TF, LTF, A1BG, VDBP, ECM1, ITIH1, HGFAC, F9, F12, KRT1, KRT10 in CADvC. Proteins ATRN, HBD, CFHR2, CFHR4, KRT9, BST1, PTGDS and SAA2-SAA4 did not share similar functions with the other proteins in the network and hence were excluded in the following functional enrichment analysis. In MADvC, proteins C2, C4A, FGA, ITIH4, APOA4 and F12 were found to interact with each other, however, the relationship of proteins EFEMP1, KRT2, KRT13 and IGFBP2 with the other correlated proteins were uncertain (Fig. 4B).

Functional enrichment analysis

For further interpretation of the biological functions and pathways of the interacted DEPs, GO enrichment analysis was performed using the ClueGO application in Cytoscape. The resulting GO terms and KEGG pathways which were significantly enriched with the interacted proteins correlated with CADvC and MADvC are shown in Fig. 5. The details of the pathways are included in Table S1. The enriched gene ontology and pathways identified using the interacted proteins in each comparison group were illustrated in Fig. 6.

Figure 5. Significant KEGG pathways and GO terms enriched.

Figure 5

(A) CADvC, (B) MADvC and the number of associated proteins found within each of the pathways. Common pathways between CADvC and MADvC were highlighted in yellow. (C) Venn diagram of the pathways identified.

Figure 6. Network depiction of the identified proteins with enriched GO categories and pathways that related to AD’s pathology in (A) CADvC, (B) MADvC.

Figure 6

Each of the nodes represents the enriched pathways and GO terms and the edges indicate the interaction between the proteins and terms. The functional groups of the biological process are represented in different colour nodes. The corresponding proteins are shown in the centre of each network. The p-value of the GO terms is illustrated by the size of the nodes: the smaller the p-value, the large the size of the nodes.

As demonstrated in Figs. 5 and 6, the dysregulated proteins identified from Chinese and Malay were similarly enriched with the pathways blood microparticle, collagen-containing extracellular matrix and transport, inflammatory response, humoral immune response, defence response and protein metabolic process.

Analysis of questionnaire survey data of the subjects by ethnicity

The sociodemographic details and medical conditions of the subjects are shown in Table 4. No significant differences were observed for most of the characteristics between Chinese and Malay ethnic groups. Nevertheless, a significant difference (p-value = 0.028) was noted when all the Malay respondents were living with family members while the living situation of the Chinese was distributed to living with spouse, family members, or others such as with maid or old folk’s home.

Table 4. Sociodemographic and medical details of the subjects.

Demographics Chinese (n = 7) Malay (n = 5) p-value
Mean ± SD/n(%)
Living area City centre 1 (14.3) 0 1
Town centre 6 (85.7) 4 (80) 1
Village 0 1 (20) 0.417
Marital status Married 4 (57.1) 5 (100) 0.205
Widow 3 (42.9) 0 0.205
Living situation Living with spouse only 3 (42.9) 0 0.205
Living with family members (e.g., spouse, siblings and children) 2 (28.6) 5 (100) 0.028
Others 2 (28.6) 0 0.47
Highest education No formal education 1 (14.3) 0 1
Primary 1 (14.3) 0 1
Secondary 1 (14.3) 2 (40) 0.523
Polytechnique/university/college 4 (57.1) 3 (60) 1
Height 159.29 ± 5.77 160.28 ± 4.65 0.744
Weight 54.14 ± 7.16 57.24 ± 8.15 0.53
Systolic blood pressure 115.86 ± 5.15 126.8 ± 21.39 0.678
Family history of AD 2 (28.6) 0 0.47
Medical conditions/history Diabetes mellitus 2 (28.6) 1 (20) 1
Hypertension 2 (28.6) 2 (40) 1
Visual disease 3 (42.9) 2 (40) 1
Heart disease 0 2 (40) 0.152
Asthma 1 (14.3) 1 (20) 1
Hepatitis 2 (28.6) 1 (20) 1
Arthritis 1 (14.3) 1 (20) 1
Others 1 (14.3) 2 (40) 0.523
History of head injury 1 (14.3) 0 1
Employment status Unemployed 1 (14.3) 0 1
Self-employed 1 (14.3) 0 1
Retired 5 (71.4) 5 (100) 1

Following the statistical analysis as shown in Table 5, the parameters surveyed in the questionnaire did not show a significant difference between Chinese and Malay subjects, except for the consumption of sweet drinks/foods; the sugar consumption of Malay patients (mean of 8.29 ± 1.05) was significantly higher compared to their Chinese counterparts (mean of 4.03 ± 1.83), with a p-value of 0.023.

Table 5. Lifestyle and physical practices of participants by ethnicity.

Practices Chinese (n = 7) Malay (n = 5) p-value
Mean ± SD/n(%)
Lifestyle and dietary practices
Duration of sleep (hours/night) 7.9 ± 0.22 7.33 ± 0.76 0.723
No. of times wake up at night (times/night) 1.2 ± 0.1 2 ± 0 0.259
Smoker Smoker 1 (14.29) 3 (60) 0.222
Never 6 (85.71) 2 (40) 0.222
Cigarettes (cigarettes/week) 20 ± 52.92 63 ± 62.61 0.208
No. of times skip meals (breakfast, lunch or dinner) (times/week) 0.19 ± 0.5 0 0.5
Eating style Vegetarian 1 (14.29) 0 1
Non-vegetarian 6 (85.71) 5 (100) 1
Fast food/fried food/food high in salt and fat (times/week) 1 ± 0 2.4 ± 1.92 0.103
Sweet drinks/food (e.g., snacks, soda, dessert, fruits) (times/week) 4.03 ± 1.83 8.29 ± 1.05 0.023
Alcohol consumption (unit/occasion) 0.6 ± 1.34 0 0.259
Physical practices
Mode of transportation Private transport 7 (100) 5 (100)
Time spent on transportation (mins/time) 12.86 ± 23.6 12 ± 16.43 0.922
No. of days of going out (days/week) 2.29 ± 1.8 2.6 ± 2.88 1
Types of outdoor activities Dining 3 (42.86) 3 (60) 1
Exercise 1 (14.29) 1(20) 1
House visit 1 (14.29) 1 (20) 1
Entertainment 1 (14.29) 1 (20) 1
Run errands 2 (28.57) 1 (20) 1
Medical appointment 7 (100) 5 (100)
Level of exercise No exercise 1 (14.29) 0 1
Light exercise 4 (57.14) 5 (100) 0.205
Moderate exercise 2 (28.57) 0 0.47
Time spent on exercise (mins/day) 14.28 ± 9.32 20 ± 7.91 0.283
Sitting (mins/day) 124.29 ± 61.06 174 ± 13.42 0.17

From Tables 4 and 5, two parameters showed significant differences between Chinese and Malay participants which are living with family members and consumption of sweet drinks/food. Next, the Pearson correlation coefficient was performed on these two parameters to find the correlation of the parameters with the Chinese and Malay groups. The correlation results are shown in Table 6. Low correlations were found for both parameters (r = 0.4 and r = −0.551 respectively) with the Chinese ethnic. As for the Malay group, all the Malay participants lived with their family members (e.g., spouse, siblings and children), hence no deviation (SD = 0) and no correlation were calculated for this parameter. On the contrary, the consumption of sweet drinks/food showed a significantly high correlation (r = 0.879, p-value = 0.049) with the Malay group.

Table 6. Pearson correlation coefficient test on the parameters of living with family members and consumption of sweet drink/food in Chinese and Malay ethnic groups.

Parameters Pearson correlation coefficient (r) (p-value)
Chinese Malays
Living with family members (e.g., spouse, siblings and children) 0.4 (0.374)
Sweet drinks/food (e.g., snacks, soda, dessert, fruits) −0.551 (0.2) 0.879 (0.049)

Meta-analysis

From the PubMed literature search, 23 articles were identified to be related and were accessed for suitability. From there, 13 articles were included in the systematic review and a total of eight studies including the outcomes from the current study were included in the meta-analysis. Tables S2 and S3 presented the forest plots of the dysregulated proteins identified in CADvC and MADvc respectively, among the AD and normal control subjects. For the meta-analysis of the dysregulated proteins identified from CADvC (Table S2), protein HGFAC was excluded from the analysis as no relevant information could be found. Meanwhile, proteins TF (SMD= −0.18, 95% CI= [−1.09 to 0.73], p = 0.01, r = 0.09), AHSG (SMD= −0.24, 95% CI = [−1.12 to 0.64], p < 0.001, r = 0.13) and A1BG (SMD = −0.21, 95% CI = [−1.89 to 1.47], p = 0.01, r = 0.11) showed significant down-regulation in AD compared to control. Notably, all of these proteins showed weak dysregulations with low effect size (r < 0.3) in the data. From the outcomes presented by the meta-analysis of the dysregulated proteins identified in MADvC (Table S3), proteins APOA4 (SMD = 0.29, 95% CI = [−0.97 to 1.55], p < 0.001, r = 0.14) and C4A (SMD = 0.24, 95% CI = [−20.59 to 21.06], p < 0.001, r = 0.39) were found to be significantly upregulated in AD compared to normal control. In this comparison group, protein APOA4 showed weak dysregulations while protein C4A showed medium dysregulation (moderate effect size, r < 0.5) among the AD group.

Discussion

This study aimed to provide new insight into Alzheimer’s disease via a study of proteomics using sampling from the two major races from the multi-ethnic population in Malaysia. It is presumed that the genetic constitution of different ethnic groups differs, thus, the gene regulation product, proteins, might on this account alone already vary (Galanter et al., 2017; Huang, Shu & Cai, 2015). However, we also felt that by looking at the proteins, rather than being confined to genomes, could at the same time encompass environmental influencers in the development of AD.

In this study, the number of samples from the Chinese (seven samples) and Malays (five samples), do not reflect the general composition of our population, in which the Chinese form 22.6% and the Malays form 69.6% of the population (Department of Statistics Malaysia, 2021). The lower number of Malays studied was due to the attendance pattern at the Memory Clinic where ~50% of the patients who visited the clinic were Chinese while only ~16% of the patients were Malays. To minimise the potential confounding related to medications and comorbidities, patients who were under palliative care for other diseases were excluded from the recruitment of the subjects in this study. Although the sample quality of AD proteomics is unavoidably affected by the cofounding factors, literature has shown that the confounding effects are relatively smaller on the analysis of whole proteome compared to that on the modified proteome (i.e., ubiquitinome and phosphatome) due to the characteristic of modified proteins which are highly unstable and dynamic (Bai et al., 2021). In the current proteomic study, the pooling strategy applied to the samples by grouping subjects with similar gender, ethnicity and disease condition together averages the confounding effects and at the same time increases the statistical power (Johnstone et al., 2012). Also, as shown from the result of the survey analysis of the demographic data, none of the possible comorbidity factors showed a significant correlation with AD (Tables 5 and 6), other than the practice of sweet intakes among the Malay population.

The results from differential expression analysis comparing CADvC and MADvC (Table 3 and Fig. 3) indicated that DEPs differed between the two ethnic groups. It suggested that different protein regulations were involved in the AD development of Chinese and Malay patients. Among the DEPs identified, Coagulation factor XII (F12) is the only protein that is commonly found among the CADvC and MADvC. There is evidence that the depletion of F12 in mice lessens fibrin deposition and lessens cognitive decline (Chen et al., 2017; Park et al., 2021). The activation of F12 triggers thrombosis in plasma which in turn induces inflammation in the AD pathogenesis pathway (Singh et al., 2021). In this study, F12 was found to show upregulated activity in CADvC but downregulated in MADvC. This shows that the roles of this protein on AD development might vary in different ethnic groups, due to the effect of different environmental factors and lifestyle practices. A study was conducted to test the average activity of F12 in the Chinese population (Han et al., 2015). Mutations were found in subjects who were detected with abnormal low activities of F12 which suggested the potential of F12 dysregulation in correlating with the Chinese population. However, our study did not support this finding and further clarification is needed to confirm this.

Despite the divergence in proteins identified between CADvC and MADvC (Figs. 5 and 6), several pathways were commonly found between the groups. Other than blood microparticles, collagen-containing extracellular matrix and transport are pathways relating to the cellular and functional component of the blood, the other pathways are found to exhibit a close connection with AD pathogenesis. As such, the cellular and molecular changes in inflammatory, humoral immune and defence responses are found to be linked with neuroinflammation, which is one of the critical factors contributing to AD pathogenesis. Inflammation response occurring in the brain is a well-established core feature for AD development (Kinney et al., 2018). On top of that, there are increasing evidences demonstrating the relationship between peripheral inflammation with cognitive dysfunction in AD (Leung et al., 2013; Park, Han & Mook-Jung, 2020). Inflammatory signals have been shown in the blood peripheral system and act as a communication route to the cytokines levels in brain (Leung et al., 2013; Park, Han & Mook-Jung, 2020). Humoral immune response, where defence response is part of the system, refers to the initiation of antibody molecule production in blood. In AD, circulating anti- antibodies such as B cells and immunoglobulins enhance neuroprotection over the development of , hence attenuating AD pathogenesis potentially (Cao & Zheng, 2018; Montero-Calle et al., 2020). The dysfunction in protein metabolism can cause neurodegenerative diseases, including AD. One of the most remarkable examples is the dysregulation in the mechanism, where the failure can lead to the accumulation of plaques in the brain (Kaddurah-Daouk et al., 2013; Montero-Calle et al., 2020; Yan et al., 2020).

In CADvC, 14 proteins showed an association with each other (Fig. 4A). These proteins showed consistent enrichment with extracellular matrix (ECM), as shown in Fig. 6A. This observation implicated the prominence of ECM in the causal pathogenesis of AD. The dysregulation of ECM has been found to be related to the development of AD in several ways, including the triggering/inhibition of Aβ aggregation, interaction with tau protein, relieving oxidative stress and reducing inflammatory response (Sun et al., 2021). This can be further corroborated by the role of the identified proteins, as shown in Table S4.

Recent studies found that the consumption of alcohol is relevant to the inflammatory mechanism in inducing AD by reducing Aβ uptake by the primary microglia (Eid, Mhatre & Richardson, 2019; Heymann et al., 2016; Kalinin et al., 2018; Langballe et al., 2015). According to the survey analysis done in this study, the habit of alcohol consumption, although it was not significant, was higher among the Chinese group. Alcohol consumption is not practised among the Malay population due to their religious belief of Islam. In accordance with these findings, this study highlighted the involvement of the dysregulated proteins identified among the Chinese group in the pathways related to an inflammatory response. Reports showed that alcohol drinkers tend to have more severe cognitive decline compared to those infrequent or non-drinkers (Eid, Mhatre & Richardson, 2019; Heymann et al., 2016; Langballe et al., 2015).

Notably, the roles of some identified proteins (e.g., ITIH1, HGFAC, A1BG, KRT1, and KRT10) in AD development are yet to be discovered. This study uncovered a group of previously unknown proteins that are associated with each other, suggesting the potential for their co-regulation on ECM-related pathways and their roles in AD pathogenesis. Hence, they might serve as potential protein markers which require attention in further research.

Meta-analysis was conducted using the set proteins identified in CADvC in order to increase the statistical power and reliability of the result of this study. The aberrant levels of proteins TF, AHSG and A1BG among AD were confirmed through the findings of the meta-analysis.

The proteins identified from the MADvC support the influence of neuroinflammation in the pathogenesis of AD. The findings of the roles of these proteins in leading to neuroinflammation further enhanced the contribution of functional terms defence response, protein metabolic process and ECM in AD pathophysiology relating to Malays. The roles of the proteins and their relationship with AD are summarized in Table S5. The reliability of the roles and functions of proteins APOA4 and C4A in AD was supported by the findings of the meta-analysis conducted in this study which showed significant upregulation activities among the AD group when compared to the normal controls.

Interestingly, the expressions of a few identified proteins were found to be influenced by the living environment factors. The association of the VDBP with ethnicity was found to be strong in several studies related to vitamin D deficiency in Malaysia (Chin et al., 2014; Rahman et al., 2004; Shafinaz & Moy, 2016). Protein VDBP functions to maintain the levels of vitamin D in plasma by promoting its reabsorption in the kidney (Bouillon et al., 2020; Rozmus et al., 2020). Previous studies indicated the association of vitamin D with Aβ clearance in the brain, attenuating neurodegeneration (Bivona et al., 2019, 2021). The consumption of nutritional supplements (including vitamin D) in the Chinese population was found to be higher compared to the other ethnicities in Malaysia (Abdullah, Teo & Foo, 2016; Saffian et al., 2021). Furthermore, sunlight exposure is the main source of vitamin D in Malaysia. The lower level of melanin content in the skin and the common clothing practices encourage higher vitamin D absorption from the sunlight in the Malaysian Chinese group (Saffian et al., 2021; Shafinaz & Moy, 2016). Hence, the higher vitamin D prevalence among the Chinese population might explain the high abundance of protein VDBP found among Chinese AD patients (Woon et al., 2019).

APOA4 is found to be involved in the regulation of blood sugar levels by improving insulin sensitivity and promoting sugar uptake (Li et al., 2017). Studies have found the expression of APOA4 to be affected by the sugar levels in the brain (Liu et al., 2004; Wang et al., 2015). In this study, APOA4 showed significantly differentiated abundance with AD in the Malay group (MADvC). The presence of APOA4 was found to lead to the deterioration of cognitive competency in healthy Malay individuals (Abu Bakar et al., 2019). In addition, the relationship of APOA4 with sugar intake in Malays is further supported by the data analysis from our survey, where there was significantly higher sugar consumption in the Malays compared to the Chinese. Numerous studies have also demonstrated marked differences in sugar intake habits across different ethnic groups, where Malays were found to have a higher affinity toward food and drinks with higher sugar levels (Cheah et al., 2019; Eng et al., 2022; Zainuddin et al., 2018).

One limitation of this study is the small sample size collected. The heterogeneity of dementia (i.e., vascular dementia, Lewy Bodies dementia, AD, etc.) with different clinical and progress presentations in patients who visited the clinics resulted in the restriction of the number of patients that could be recruited into this study. Furthermore, as blood sampling is an invasive sampling method, some of the patients refused to provide consent. As a result, recruitment was limited restricting the proteomic analysis. Limited sample size in the proteomic study can lead to biased results and conclusions and to overcome this, the multiplex strategy of pooling samples was applied in this study. The samples were pooled according to gender and disease condition of the respective ethnicity of the subjects so that similar proteins from different samples but the same ethnicity could be eluted at the same mass-to-charge ratio (m/z) and at the same time. By this, the relative abundances of different proteins could be directly compared and the problem of the bias can be reduced (Arul & Robinson, 2018).

In this study, the differential protein analysis was carried out using limma with proteins of adjusted p-value < 0.05 considered significant aberrant. Notably, log2FC was not applied as a filtering criterion in selecting differentiated proteins but used as a marking value in evaluating the regulation of the dysregulated proteins. Imposing fold change on a small sample size experiment often causes uncertainty in the sample variability estimation (Kammers et al., 2015). The application of a commonly used fold change threshold (i.e., 1.5) could also result in the loss of information or unreproducible outcomes (Schwammle, León & Jensen, 2013). Besides that, to reduce the compulsion imposed by the small sample size of this experiment, moderated t-statistics rather than the ordinary t-test was computed using the empirical Bayes method in limma. The statistical principles implemented in limma help to reduce the problems inherited in small experiments. The statistical method of empirical Bayes allows the “borrowing” of strength between the proteins in a dynamic way, reducing the number of false positive and false negative rates (Kammers et al., 2015; Ritchie et al., 2015). Hence, the statistical power and reliability of the results were improved for experiments with a small number of replicates, as contained in this study (Ritchie et al., 2015).

This study suggests the preliminary proteomic profiles of AD in Chinese and Malay groups in Malaysia. Although the findings of this study are consistent with the literature, they nonetheless represent the dysregulation of proteins found within a small sample size dataset and will require further validation. First, the expression of the selected biomarkers from this study could be confirmed through in vitro experiments such as absolute protein quantification. Next, future research should also expand towards the deep evaluation of the described mechanisms/networks identified in this study such as using bioimaging techniques to effectively improve the chances of reducing neuroinflammation/ metabolic dysregulation that leads to AD pathogenesis. Thirdly, the prospects should include more subjects in future studies and expand to the other ethnicities in Malaysia. The multi-cultural genetic constitution could provide a better understanding of AD pathogenesis by bridging the genetic, molecular and network factors to different behavioural/environmental factors. Furthermore, the proposed method could be expanded into multi-omics analysis to include more data from the other omics (i.e., transcriptomics and metabolomics) so that the characteristics, functions and mechanisms from the other omics could be linked and connected. Further investigations may provide an opportunity to evaluate the understanding of AD pathogenesis and different physiological mechanisms together with the physical environment in designing new diagnostic approaches/therapies.

Conclusions

The expansion of the ageing population has indirectly led to the increment of AD cases reported. With regard to that, the study of the interaction between the dysregulated proteins may provide an understanding of the characterization of AD pathophysiology. The variation of protein abundances in different ethnic populations that are possibly affected by different behavioural practices caught more attention in the research relating to AD study. This study proposes an integrated method that combines proteomic profiling and differential expression analysis between AD patients and normal controls for Chinese and Malays in Malaysia. The pathways and protein-protein interactions of the identified protein signatures were analyzed using functional enrichment analysis. The results showed that the dysregulated proteins identified from Chinese samples were significantly enriched to the pathway leading to Aβ/tau protein, oxidative stress and inflammation and the dysregulated proteins for Malay groups were more related to neuroinflammation. The results were supported by previous studies on the developmental mechanisms of AD in Malaysia, especially among the Chinese and Malay populations. The survey conducted further interpreted the impact of different lifestyle practices on the variation of dysregulated protein identified in this study. The significant difference in sugar consumption practices between Chinese and Malay groups supports the relation of dysregulated APOA4 protein in the Malay groups. An additional meta-analysis conducted further supported the significant aberrances in levels of proteins TF, AHSG, A1BG, APOA4 and C4A among AD patients compared to the normal controls. This study suggests preliminary findings on AD-related proteomics analysis and its relation to the environmental factors in Chinese and Malay populations in Malaysia. This effort should be expanded to include more subjects and ethnicities to have a better understanding of the pathogenesis of AD in Malaysia.

Supplemental Information

Supplemental Information 1. Significant KEGG pathways and GO terms enriched for CADvC and MADvC.
peerj-12-17643-s001.docx (24.4KB, docx)
DOI: 10.7717/peerj.17643/supp-1
Supplemental Information 2. Forest plots for abundance levels of the dysregulated proteins identified in CADvC among groups of AD patient vs normal control.

Note: Blue dot (Hedges’ g) represents the SMD for each individual study where the positive value indicates higher levels of proteins in AD compared to normal controls. Green dot indicates the total SMD controlled by the combined effects of prediction interval (PI) and confidence interval (CI). Total SMD with positive value indicates upregulation of the proteins in AD group.

peerj-12-17643-s002.docx (139.9KB, docx)
DOI: 10.7717/peerj.17643/supp-2
Supplemental Information 3. Forest plots for abundance levels of the dysregulated proteins identified in MADvC among groups of AD patient vs normal controls.

Note: Blue dot (Hedges’ g) represents the SMD for each individual study where the positive value indicates higher levels of proteins in AD compared to normal controls. Green dot indicates the total SMD controlled by the combined effects of prediction interval (PI) and confidence interval (CI). Total SMD with positive value indicates upregulation of the proteins in AD group.

peerj-12-17643-s003.docx (61.5KB, docx)
DOI: 10.7717/peerj.17643/supp-3
Supplemental Information 4
peerj-12-17643-s004.docx (38.4KB, docx)
DOI: 10.7717/peerj.17643/supp-4
Supplemental Information 5
peerj-12-17643-s005.docx (27.2KB, docx)
DOI: 10.7717/peerj.17643/supp-5
Supplemental Information 6. Supplementary Methods.
peerj-12-17643-s006.docx (20.5KB, docx)
DOI: 10.7717/peerj.17643/supp-6
Supplemental Information 7. The full version of HC using 163 proteins.
DOI: 10.7717/peerj.17643/supp-7
Supplemental Information 8. Sociodemographic, lifestyle and physical questionnaire.
peerj-12-17643-s008.docx (37.4KB, docx)
DOI: 10.7717/peerj.17643/supp-8
Supplemental Information 9. Dataset for survey analysis.
peerj-12-17643-s009.xlsx (16.9KB, xlsx)
DOI: 10.7717/peerj.17643/supp-9
Supplemental Information 10. STROBE checklist.
peerj-12-17643-s010.doc (81.5KB, doc)
DOI: 10.7717/peerj.17643/supp-10

Funding Statement

This work was supported by the UM International Collaboration Grant, project number ST041-2022 and the Fundamental Research Grant Scheme (FRGS), Ministry of Higher Education Malaysia, project number FRGS/1/2019/SKK06/UM/02/5. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Additional Information and Declarations

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

Mei Sze Tan conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.

Phaik-Leng Cheah conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Ai-Vyrn Chin conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Lai-Meng Looi conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Siow-Wee Chang conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

This study was approved by the Universiti Malaya Medical Centre (UMMC) Medical Research Ethics Committee (2020114-9193).

Data Availability

The following information was supplied regarding data availability:

The mass spectrometry proteomics data are available at the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository: PXD040566.

The raw data for the survey analysis is available in the Supplemental File.

References

  • Abdullah, Teo & Foo (2016).Abdullah N-F, Teo PS, Foo LH. Ethnic differences in the food intake patterns and its associated factors of adolescents in Kelantan. Malaysia Nutrients. 2016;8(9):551. doi: 10.3390/nu8090551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Abu Bakar et al. (2019).Abu Bakar ZH, Damanhuri HA, Makpol S, Wan Kamaruddin WMA, Abdul Sani NF, Amir Hamzah AIZ, Nor Aripin KN, Mohd Rani MD, Noh NA, Razali R, Mazlan M, Abdul Hamid H, Mohamad M, Wan Ngah WZ. Effect of age on the protein profile of healthy Malay adults and its association with cognitive function competency. Journal of Alzheimer’s Disease. 2019;70(s1):S43–S62. doi: 10.3233/JAD-180511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Alzheimer’s Association (2020).Alzheimer’s Association 2020 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2020;16(3):391–460. doi: 10.1002/alz.12068. [DOI] [Google Scholar]
  • Alzheimer’s Disease International et al. (2015).Alzheimer’s Disease International. Wimo A, Ali G-C, Guerchet M, Prince M, Prina M, Wu Y-T. London: Alzheimer’s Disease International; 2015. World Alzheimer report 2015-the global impact of dementia: an analysis of prevalence, incidence, cost and trends. [Google Scholar]
  • Arul & Robinson (2018).Arul AB, Robinson RA. Sample multiplexing strategies in quantitative proteomics. Analytical Chemistry. 2018;91(1):178–189. doi: 10.1021/acs.analchem.8b05626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bai et al. (2021).Bai B, Vanderwall D, Li Y, Wang X, Poudel S, Wang H, Dey KK, Chen P-C, Yang K, Peng J. Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery. Molecular Neurodegeneration. 2021;16(1):55. doi: 10.1186/s13024-021-00474-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bai et al. (2020).Bai B, Wang X, Li Y, Chen P-C, Yu K, Dey KK, Yarbro JM, Han X, Lutz BM, Rao S, Jiao Y, Sifford JM, Han J, Wang M, Tan H, Shaw TI, Cho J-H, Zhou S, Wang H, Niu M, Mancieri A, Messler KA, Sun X, Wu Z, Pagala V, High AA, Bi W, Zhang H, Chi H, Haroutunian V, Zhang B, Beach TG, Yu G, Peng J. Deep multilayer brain proteomics identifies molecular networks in Alzheimer’s disease progression. Neuron. 2020;105(6):975–991.e977. doi: 10.1016/j.neuron.2019.12.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bindea et al. (2009).Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman W-H, Pagès F, Trajanoski Z, Galon J. ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091–1093. doi: 10.1093/bioinformatics/btp101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bivona et al. (2019).Bivona G, Gambino CM, Iacolino G, Ciaccio M. Vitamin D and the nervous system. Neurological Research. 2019;41(9):827–835. doi: 10.1080/01616412.2019.1622872. [DOI] [PubMed] [Google Scholar]
  • Bivona et al. (2021).Bivona G, Lo Sasso B, Gambino CM, Giglio RV, Scazzone C, Agnello L, Ciaccio M. The role of vitamin D as a biomarker in Alzheimer’s disease. Brain Sciences. 2021;11(3):334. doi: 10.3390/brainsci11030334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bouillon et al. (2020).Bouillon R, Schuit F, Antonio L, Rastinejad F. Vitamin D binding protein: a historic overview. Frontiers in Endocrinology. 2020;910:1078. doi: 10.3389/fendo.2019.00910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Cao & Zheng (2018).Cao W, Zheng H. Peripheral immune system in aging and Alzheimer’s disease. Molecular Neurodegeneration. 2018;13(1):58. doi: 10.1186/s13024-018-0290-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Cheah et al. (2019).Cheah YK, Abdul Adzis A, Abu Bakar J, Applanaidu SD. Factors associated with consumption of sugar-sweetened foods and beverages in Malaysia: an ethnic comparison. International Journal of Diabetes in Developing Countries. 2019;39(3):568–578. doi: 10.1007/s13410-018-0673-7. [DOI] [Google Scholar]
  • Chen et al. (2017).Chen Z-L, Revenko AS, Singh P, MacLeod AR, Norris EH, Strickland S. Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice. Blood, The Journal of the American Society of Hematology. 2017;129(18):2547–2556. doi: 10.1182/blood-2016-11-753202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Chin et al. (2014).Chin K-Y, Ima-Nirwana S, Ibrahim S, Mohamed IN, Wan Ngah WZ. Vitamin D status in Malaysian men and its associated factors. Nutrients. 2014;6(12):5419–5433. doi: 10.3390/nu6125419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Daffner (2000).Daffner KR. Early Diagnosis of Alzheimer’s Disease. Cham: Springer; 2000. Current approaches to the clinical diagnosis of Alzheimer’s disease; pp. 29–64. [Google Scholar]
  • Department of Statistics Malaysia (2021).Department of Statistics Malaysia . Current population estimates. Putrajaya: Department of Statistics Malaysia; 2021. [Google Scholar]
  • Eid, Mhatre & Richardson (2019).Eid A, Mhatre I, Richardson JR. Gene-environment interactions in Alzheimer’s disease: a potential path to precision medicine. Pharmacology & Therapeutics. 2019;199(3):173–187. doi: 10.1016/j.pharmthera.2019.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Eng et al. (2022).Eng CW, Lim SC, Ngongo C, Sham ZH, Kataria I, Chandran A, Mustapha FI. Dietary practices, food purchasing, and perceptions about healthy food availability and affordability: a cross-sectional study of low-income Malaysian adults. BMC Public Health. 2022;22(1):192. doi: 10.1186/s12889-022-12598-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Galanter et al. (2017).Galanter JM, Gignoux CR, Oh SS, Torgerson D, Pino-Yanes M, Thakur N, Eng C, Hu D, Huntsman S, Farber HJ, Avila PC, Brigino-Buenaventura E, LeNoir MA, Meade K, Serebrisky D, Rodríguez-Cintrón W, Kumar R, Rodríguez-Santana JR, Seibold MA, Borrell LN, Burchard EG, Zaitlen N. Differential methylation between ethnic sub-groups reflects the effect of genetic ancestry and environmental exposures. eLife. 2017;6:e20532. doi: 10.7554/eLife.20532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Han et al. (2015).Han Y, Zhu T, Jiao L, Hua B, Cai H, Zhao Y. Normal range and genetic analysis of coagulation factor XII in the general Chinese population. Thrombosis Research. 2015;136(2):440–444. doi: 10.1016/j.thromres.2015.06.012. [DOI] [PubMed] [Google Scholar]
  • Heymann et al. (2016).Heymann D, Stern Y, Cosentino S, Tatarina-Nulman O, N. Dorrejo J, Gu Y. The association between alcohol use and the progression of Alzheimer’s disease. Current Alzheimer Research. 2016;13(12):1356–1362. doi: 10.2174/1567205013666160603005035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Huang, Shu & Cai (2015).Huang T, Shu Y, Cai Y-D. Genetic differences among ethnic groups. BMC Genomics. 2015;16(1):1093. doi: 10.1186/s12864-015-2328-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • International Service for the Acquisition of Agri-biotech Applications (2006).International Service for the Acquisition of Agri-biotech Applications . Pocket K No. 15: ‘Omics’ sciences: genomics, proteomics, and metabolomics. 2006. [Google Scholar]
  • Janelidze et al. (2016).Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, Van Westen D, Jeromin A, Song L, Hanlon D, Hehir CAT, Baker D, Blennow K, Hansson O. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Scientific Reports. 2016;6(1):26801. doi: 10.1038/srep26801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Jansen et al. (2019).Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Brækhus A, Bråthen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rognve A, Saltvedt I, Sando SB, Selbæk G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nature Genetics. 2019;51(3):404–413. doi: 10.1038/s41588-018-0311-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Johnstone et al. (2012).Johnstone D, Milward EA, Berretta R, Moscato P, Alzheimer’s Disease Neuroimaging Initiative Multivariate protein signatures of pre-clinical Alzheimer’s disease in the Alzheimer’s disease neuroimaging initiative (ADNI) plasma proteome dataset. PLOS ONE. 2012;7:e34341. doi: 10.1371/journal.pone.0034341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Kaddurah-Daouk et al. (2013).Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen S, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM, Arnold SE, Pharmacometabolomics Research Network Alterations in metabolic pathways and networks in Alzheimer’s disease. Translational Psychiatry. 2013;3:e244. doi: 10.1038/tp.2013.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Kalinin et al. (2018).Kalinin S, González-Prieto M, Scheiblich H, Lisi L, Kusumo H, Heneka MT, Madrigal JLM, Pandey SC, Feinstein DL. Transcriptome analysis of alcohol-treated microglia reveals downregulation of beta amyloid phagocytosis. Journal of Neuroinflammation. 2018;15(1):141. doi: 10.1186/s12974-018-1184-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Kammers et al. (2015).Kammers K, Cole RN, Tiengwe C, Ruczinski I. Detecting significant changes in protein abundance. EuPA Open Proteomics. 2015;7:11–19. doi: 10.1016/j.euprot.2015.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Kinney et al. (2018).Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2018;4(1):575–590. doi: 10.1016/j.trci.2018.06.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Langballe et al. (2015).Langballe EM, Ask H, Holmen J, Stordal E, Saltvedt I, Selbæk G, Fikseaunet A, Bergh S, Nafstad P, Tambs K. Alcohol consumption and risk of dementia up to 27 years later in a large, population-based sample: the HUNT study, Norway. European Journal of Epidemiology. 2015;30(9):1049–1056. doi: 10.1007/s10654-015-0029-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Leung et al. (2013).Leung R, Proitsi P, Simmons A, Lunnon K, Güntert A, Kronenberg D, Pritchard M, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Soininen H, Wahlund L-O, Lovestone S. Inflammatory proteins in plasma are associated with severity of Alzheimer’s disease. PLOS ONE. 2013;8:e64971. doi: 10.1371/journal.pone.0064971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Li et al. (2017).Li X, Wang F, Xu M, Howles P, Tso P. ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signaling. Scientific Reports. 2017;7:41289. doi: 10.1038/srep41289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Liu, Beyer & Aebersold (2016).Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell. 2016;165:535–550. doi: 10.1016/j.cell.2016.03.014. [DOI] [PubMed] [Google Scholar]
  • Liu et al. (2004).Liu M, Shen L, Liu Y, Tajima D, Sakai R, Woods SC, Tso P. Diurnal rhythm of apolipoprotein A-IV in rat hypothalamus and its relation to food intake and corticosterone. Endocrinology. 2004;145:3232–3238. doi: 10.1210/en.2003-1554. [DOI] [PubMed] [Google Scholar]
  • Madrid et al. (2021).Madrid L, Labrador SC, González-Pérez A, Sáez ME, Alzheimer’s Disease Neuroimaging Initiative Integrated genomic, transcriptomic and proteomic analysis for identifying markers of Alzheimer’s disease. Diagnostics. 2021;11(12):2303. doi: 10.3390/diagnostics11122303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Montero-Calle et al. (2020).Montero-Calle A, Segundo-Acosta S, Garranzo-Asensio M, Rábano A, Barderas R. The molecular misreading of APP and UBB induces a humoral immune response in Alzheimer’s disease patients with diagnostic ability. Molecular Neurobiology. 2020;57(2):1009–1020. doi: 10.1007/s12035-019-01809-0. [DOI] [PubMed] [Google Scholar]
  • Mucke (2009).Mucke L. Alzheimer’s disease. Nature. 2009;461(7266):895–897. doi: 10.1038/461895a. [DOI] [PubMed] [Google Scholar]
  • Park, Han & Mook-Jung (2020).Park J-C, Han S-H, Mook-Jung I. Peripheral inflammatory biomarkers in Alzheimer’s disease: a brief review. BMB Reports. 2020;53(1):10–19. doi: 10.5483/BMBRep.2020.53.1.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Park et al. (2021).Park JE, Lim DS, Cho YH, Choi KY, Lee JJ, Kim BC, Lee KH, Lee JS. Plasma contact factors as novel biomarkers for diagnosing Alzheimer’s disease. Biomarker Research. 2021;9(1):5. doi: 10.1186/s40364-020-00258-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Patel, Dobson & Newhouse (2019).Patel H, Dobson RJ, Newhouse SJ. A meta-analysis of Alzheimer’s disease brain transcriptomic data. Journal of Alzheimer’s Disease. 2019;68(4):1635–1656. doi: 10.3233/JAD-181085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Perez-Riverol et al. (2022).Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S, Kundu DJ, Prakash A, Frericks-Zipper A, Eisenacher M, Walzer M, Wang S, Brazma A, Vizcaíno JA. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Research. 2022;50(D1):D543–D552. doi: 10.1093/nar/gkab1038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Rahman et al. (2004).Rahman SA, Chee W, Yassin Z, Chan SP. Vitamin D status among postmenopausal Malaysian women. Asia Pacific Journal of Clinical Nutrition. 2004;13:255–260. [PubMed] [Google Scholar]
  • Rehiman et al. (2020a).Rehiman SH, Lim SM, Lim FT, Chin A-V, Tan MP, Kamaruzzaman SB, Ramasamy K, Abdul Majeed AB. Fibrinogen isoforms as potential blood-based biomarkers of Alzheimer’s disease using a proteomics approach. International Journal of Neuroscience. 2020a;132(10):1014–1025. doi: 10.1080/00207454.2020.1860038. [DOI] [PubMed] [Google Scholar]
  • Rehiman et al. (2020b).Rehiman SH, Lim SM, Neoh CF, Majeed ABA, Chin A-V, Tan MP, Kamaruzzaman SB, Ramasamy K. Proteomics as a reliable approach for discovery of blood-based Alzheimer’s disease biomarkers: a systematic review and meta-analysis. Ageing Research Reviews. 2020b;60:101066. doi: 10.1016/j.arr.2020.101066. [DOI] [PubMed] [Google Scholar]
  • Ritchie et al. (2015).Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015;43(7):e47. doi: 10.1093/nar/gkv007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Rozmus et al. (2020).Rozmus D, Ciesielska A, Płomiński J, Grzybowski R, Fiedorowicz E, Kordulewska N, Savelkoul H, Kostyra E, Cieślińska A. Vitamin D binding protein (VDBP) and its gene polymorphisms—the risk of malignant tumors and other diseases. International Journal of Molecular Sciences. 2020;21(21):7822. doi: 10.3390/ijms21217822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Saffian et al. (2021).Saffian SM, Jamil NA, Tahir NAM, Hatah E. Vitamin D insufficiency is high in Malaysia: a systematic review and meta-analysis of studies on vitamin D status in Malaysia. Frontiers in Nutrition. 2021;9:1050745. doi: 10.3389/fnut.2022.1050745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Schwammle, León & Jensen (2013).Schwammle V, León IR, Jensen ON. Assessment and improvement of statistical tools for comparative proteomics analysis of sparse data sets with few experimental replicates. Journal of Proteome Research. 2013;12(9):3874–3883. doi: 10.1021/pr400045u. [DOI] [PubMed] [Google Scholar]
  • Shafinaz & Moy (2016).Shafinaz I, Moy F. Vitamin D level and its association with adiposity among multi-ethnic adults in Kuala Lumpur, Malaysia: a cross sectional study. BMC Public Health. 2016;16(1):232. doi: 10.1186/s12889-016-2924-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Shen et al. (2017).Shen L, Liao L, Chen C, Guo Y, Song D, Wang Y, Chen Y, Zhang K, Ying M, Li S, Liu Q, Ni J. Proteomics analysis of blood serums from Alzheimer’s disease patients using iTRAQ labeling technology. Journal of Alzheimer’s Disease. 2017;56(1):361–378. doi: 10.3233/JAD-160913. [DOI] [PubMed] [Google Scholar]
  • Singh et al. (2021).Singh PK, Badimon A, Chen ZL, Strickland S, Norris EH. The contact activation system and vascular factors as alternative targets for Alzheimer’s disease therapy. Research and Practice in Thrombosis and Haemostasis. 2021;5(4):e12504. doi: 10.1002/rth2.12504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Su et al. (2019).Su L, Chen S, Zheng C, Wei H, Song X. Meta-analysis of gene expression and identification of biological regulatory mechanisms in Alzheimer’s disease. Frontiers in Neuroscience. 2019;13:633. doi: 10.3389/fnins.2019.00633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Sun et al. (2021).Sun Y, Xu S, Jiang M, Liu X, Yang L, Bai Z, Yang Q. Role of the extracellular matrix in Alzheimer’s disease. Frontiers in Aging Neuroscience. 2021;13:707466. doi: 10.3389/fnagi.2021.707466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Suurmond, van Rhee & Hak (2017).Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis. Research Synthesis Methods. 2017;8(4):537–553. doi: 10.1002/jrsm.1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Szklarczyk et al. (2019).Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, von Mering C. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research. 2019;47(D1):D607–D613. doi: 10.1093/nar/gky1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Tan et al. (2021).Tan MS, Cheah P-L, Chin A-V, Looi L-M, Chang S-W. A review on omics-based biomarkers discovery for Alzheimer’s disease from the bioinformatics perspectives: Statistical approach vs machine learning approach. Computers in Biology and Medicine. 2021;139:104947. doi: 10.1016/j.compbiomed.2021.104947. [DOI] [PubMed] [Google Scholar]
  • Wang et al. (2015).Wang F, Kohan AB, Lo C-M, Liu M, Howles P, Tso P. Apolipoprotein A-IV: a protein intimately involved in metabolism. Journal of Lipid Research. 2015;56:1403–1418. doi: 10.1194/jlr.R052753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wightman et al. (2020).Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Rongve A, Børte S, Winsvold BS, Drange OK, Martinsen AE, Skogholt AH, Willer C, Bråthen G, Bosnes I, Nielsen JB, Fritsche L, Thomas LF, Pedersen LM, Gabrielsen ME, Johnsen MB, Meisingset TW, Zhou W, Proitsi P, Hodges A, Dobson R, Velayudhan L, 23andMe Research Team. Sealock JM, Davis LK, Pedersen NL, Reynolds CA, Karlsson IK, Magnusson S, Stefansson H, Thordardottir S, Jonsson PV, Snaedal J, Zettergren A, Skoog I, Kern S, Waern M, Zetterberg H, Blennow K, Stordal E, Hveem K, Zwart J-A, Athanasiu L, Saltvedt I, Sando SB, Ulstein I, Djurovic S, Fladby T, Aarslad D, Selbæk G, Ripke S, Stefansson K, Andreassen OA, Posthuma D. Largest GWAS (N= 1,126,563) of Alzheimer’s disease implicates microglia and immune cells. 2020. MedRxiv preprint. [DOI]
  • Woon et al. (2019).Woon FC, Chin YS, Ismail IH, Batterham M, Abdul Latiff AH, Gan WY, Appannah G, Mohammed Hussien SH, Edi M, Tan ML, Chan YM. Vitamin D deficiency during pregnancy and its associated factors among third trimester Malaysian pregnant women. PLOS ONE. 2019;14:e0216439. doi: 10.1371/journal.pone.0216439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wu et al. (2021).Wu B, Qiao J, Wang X, Liu M, Xu S, Sun D. Factors affecting the rapid changes of protein under short-term heat stress. BMC Genomics. 2021;22(1):263. doi: 10.1186/s12864-021-07560-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Yan et al. (2020).Yan X, Hu Y, Wang B, Wang S, Zhang X. Metabolic dysregulation contributes to the progression of Alzheimer’s disease. Frontiers in Neuroscience. 2020;14:530219. doi: 10.3389/fnins.2020.530219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Yao et al. (2019).Yao F, Zhang K, Zhang Y, Guo Y, Li A, Xiao S, Liu Q, Shen L, Ni J. Identification of blood biomarkers for Alzheimer’s disease through computational prediction and experimental validation. Frontiers in Neurology. 2019;9:1158. doi: 10.3389/fneur.2018.01158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Zahid et al. (2014).Zahid S, Oellerich M, Asif AR, Ahmed N. Differential expression of proteins in brain regions of Alzheimer’s disease patients. Neurochemical Research. 2014;39(1):208–215. doi: 10.1007/s11064-013-1210-1. [DOI] [PubMed] [Google Scholar]
  • Zainuddin et al. (2018).Zainuddin NS, Shahar S, Safii NS, Haron H, Omar MA. Sugar intake and metabolic syndrome among older adults in Peninsular Malaysia. Malaysian Journal of Nutrition. 2018;24(2):163–174. [Google Scholar]
  • Zetterberg & Burnham (2019).Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer’s disease. Molecular Brain. 2019;12(1):26. doi: 10.1186/s13041-019-0448-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Further Reading

  • Ashraf et al. (2020).Ashraf A, Ashton NJ, Chatterjee P, Goozee K, Shen K, Fripp J, Ames D, Rowe C, Masters CL, Villemagne V. Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology. Alzheimer’s Research & Therapy. 2020;12(1):1–13. doi: 10.1186/s13195-020-00634-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Begic et al. (2020).Begic E, Hadzidedic S, Obradovic S, Begic Z, Causevic M. Increased levels of coagulation factor XI in plasma are related to Alzheimer’s disease diagnosis. Journal of Alzheimer’s Disease. 2020;77(1):1–12. doi: 10.3233/JAD-200358. [DOI] [PubMed] [Google Scholar]
  • Bennett et al. (2012).Bennett S, Grant M, Creese AJ, Mangialasche F, Cecchetti R, Cooper HJ, Mecocci P, Aldred S. Plasma levels of complement 4a protein are increased in Alzheimer’s disease. Alzheimer Disease & Associated Disorders. 2012;26(4):329–334. doi: 10.1097/WAD.0b013e318239dcbd. [DOI] [PubMed] [Google Scholar]
  • Bermejo-Pareja et al. (2020).Bermejo-Pareja F, Del Ser T, Valentí M, de la Fuente M, Bartolome F, Carro E. Salivary lactoferrin as biomarker for Alzheimer’s disease: brain-immunity interactions. Alzheimer’s & Dementia. 2020;16(8):1196–1204. doi: 10.1002/alz.12107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bian et al. (2021).Bian Z, Yamashita T, Shi X, Feng T, Yu H, Hu X, Hu X, Bian Y, Sun H, Tadokoro K. Accelerated accumulation of fibrinogen peptide chains with Aβ deposition in Alzheimer’s disease (AD) mice and human AD brains. Brain Research. 2021;1767(34):147569. doi: 10.1016/j.brainres.2021.147569. [DOI] [PubMed] [Google Scholar]
  • Bishnoi, Palmer & Royall (2015).Bishnoi RJ, Palmer RF, Royall DR. Vitamin D binding protein as a serum biomarker of Alzheimer’s disease. Journal of Alzheimer’s Disease. 2015;43(1):37–45. doi: 10.3233/JAD-140042. [DOI] [PubMed] [Google Scholar]
  • Chen & Xia (2020).Chen M, Xia W. Proteomic profiling of plasma and brain tissue from Alzheimer’s disease patients reveals candidate network of plasma biomarkers. Journal of Alzheimer’s Disease. 2020;76(1):349–368. doi: 10.3233/JAD-200110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Cui et al. (2011).Cui Y, Huang M, He Y, Zhang S, Luo Y. Genetic ablation of apolipoprotein A-IV accelerates Alzheimer’s disease pathogenesis in a mouse model. The American Journal of Pathology. 2011;178(3):1298–1308. doi: 10.1016/j.ajpath.2010.11.057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • De Luca et al. (2017).De Luca C, Virtuoso A, Maggio N, Papa M. Neuro-coagulopathy: blood coagulation factors in central nervous system diseases. International Journal of Molecular Sciences. 2017;18(10):2128. doi: 10.3390/ijms18102128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Du et al. (2014a).Du X, Qiu S, Wang Z, Wang R, Wang C, Tian J, Liu Q. Direct interaction between selenoprotein P and tubulin. International Journal of Molecular Sciences. 2014a;15(6):10199–10214. doi: 10.3390/ijms150610199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Du et al. (2014b).Du X, Zheng Y, Wang Z, Chen Y, Zhou R, Song G, Ni J, Liu Q. Inhibitory act of selenoprotein P on Cu+/Cu2+-induced tau aggregation and neurotoxicity. Inorganic Chemistry. 2014b;53(20):11221–11230. doi: 10.1021/ic501788v. [DOI] [PubMed] [Google Scholar]
  • Eldem et al. (2022).Eldem E, Barve A, Sallin O, Foucras S, Annoni J-M, Schmid AW, Alberi Auber L. Salivary proteomics identifies transthyretin as a biomarker of early dementia conversion. Journal of Alzheimer’s Disease Reports. 2022;6(1):31–41. doi: 10.3233/ADR-210056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Festoff & Citron (2019).Festoff BW, Citron BA. Thrombin and the coag-inflammatory nexus in neurotrauma, ALS, and other neurodegenerative disorders. Frontiers in Neurology. 2019;10:59. doi: 10.3389/fneur.2019.00059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Ficiarà et al. (2021).Ficiarà E, Munir Z, Boschi S, Caligiuri ME, Guiot C. Alteration of iron concentration in Alzheimer’s disease as a possible diagnostic biomarker unveiling ferroptosis. International Journal of Molecular Sciences. 2021;22(9):4479. doi: 10.3390/ijms22094479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • François et al. (2022).François M, Karpe AV, Liu J-W, Beale DJ, Hor M, Hecker J, Faunt J, Maddison J, Johns S, Doecke JD. Multi-omics, an integrated approach to identify novel blood biomarkers of Alzheimer’s disease. Metabolites. 2022;12(10):949. doi: 10.3390/metabo12100949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Geroldi et al. (2005).Geroldi D, Minoretti P, Bianchi M, Di Vito C, Reino M, Bertona M, Emanuele E. Genetic association of alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset Alzheimer’s disease in Italians. Neuroscience Letters. 2005;386(3):176–178. doi: 10.1016/j.neulet.2005.06.014. [DOI] [PubMed] [Google Scholar]
  • Goodman (2006).Goodman AB. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. Journal of Cellular Physiology. 2006;209(3):598–603. doi: 10.1002/jcp.20784. [DOI] [PubMed] [Google Scholar]
  • Guan et al. (2020).Guan J, Wang P, Lu L, Zhao G. Association of plasma transferrin with cognitive decline in patients with mild cognitive impairment and Alzheimer’s disease. Frontiers in Aging Neuroscience. 2020;12:38. doi: 10.3389/fnagi.2020.00038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Jeon et al. (2019).Jeon SG, Cha M-Y, Kim J-I, Hwang TW, Kim KA, Kim TH, Song KC, Kim J-J, Moon M. Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer’s disease-related pathology in 5XFAD mice. Nanomedicine: Nanotechnology, Biology and Medicine. 2019;17:297–307. doi: 10.1016/j.nano.2019.02.004. [DOI] [PubMed] [Google Scholar]
  • Jiang et al. (2022).Jiang R, Smailovic U, Haytural H, Tijms BM, Li H, Haret RM, Shevchenko G, Chen G, Abelein A, Gobom J. Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis. Acta Neuropathologica Communications. 2022;10:1–17. doi: 10.1186/s40478-022-01398-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Khoonsari et al. (2019).Khoonsari PE, Shevchenko G, Herman S, Remnestål J, Giedraitis V, Brundin R, Degerman Gunnarsson M, Kilander L, Zetterberg H, Nilsson P. Improved differential diagnosis of Alzheimer’s disease by integrating ELISA and mass spectrometry-based cerebrospinal fluid biomarkers. Journal of Alzheimer’s Disease. 2019;67(2):639–651. doi: 10.3233/JAD-180855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Kitamura et al. (2017).Kitamura Y, Usami R, Ichihara S, Kida H, Satoh M, Tomimoto H, Murata M, Oikawa S. Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer’s disease. Neurological Research. 2017;39(3):231–238. doi: 10.1080/01616412.2017.1281195. [DOI] [PubMed] [Google Scholar]
  • Kononikhin et al. (2022).Kononikhin AS, Zakharova NV, Semenov SD, Bugrova AE, Brzhozovskiy AG, Indeykina MI, Fedorova YB, Kolykhalov IV, Strelnikova PA, Ikonnikova AY. Prognosis of Alzheimer’s disease using quantitative mass spectrometry of human blood plasma proteins and machine learning. International Journal of Molecular Sciences. 2022;23(14):7907. doi: 10.3390/ijms23147907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Lin, Cao & Gao (2015).Lin Q, Cao Y, Gao J. Decreased expression of the APOA1-APOC3–APOA4 gene cluster is associated with risk of Alzheimer’s disease. Drug Design, Development and Therapy. 2015;9:5421. doi: 10.2147/DDDT.S89279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Llano et al. (2013).Llano DA, Devanarayan V, Simon AJ, Alzheimer’s Disease Neuroimaging Initiative Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Disease & Associated Disorders. 2013;27(3):233–243. doi: 10.1097/WAD.0b013e31826d597a. [DOI] [PubMed] [Google Scholar]
  • Mohamed, Salama & Schaalan (2019).Mohamed WA, Salama RM, Schaalan MF. A pilot study on the effect of lactoferrin on Alzheimer’s disease pathological sequelae: impact of the p-Akt/PTEN pathway. Biomedicine & Pharmacotherapy. 2019;111(Pt A):714–723. doi: 10.1016/j.biopha.2018.12.118. [DOI] [PubMed] [Google Scholar]
  • Moon et al. (2013).Moon M, Song H, Hong H, Nam D, Cha M, Oh M, Yu J, Ryu H, Mook-Jung I. Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology. Cell Death & Differentiation. 2013;20(4):630–638. doi: 10.1038/cdd.2012.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Nielsen et al. (2021).Nielsen JE, Honoré B, Vestergård K, Maltesen RG, Christiansen G, Bøge AU, Kristensen SR, Pedersen S. Shotgun-based proteomics of extracellular vesicles in Alzheimer’s disease reveals biomarkers involved in immunological and coagulation pathways. Scientific Reports. 2021;11(1):18518. doi: 10.1038/s41598-021-97969-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Plucińska et al. (2016).Plucińska K, Dekeryte R, Koss D, Shearer K, Mody N, Whitfield PD, Doherty MK, Mingarelli M, Welch A, Riedel G. Neuronal human BACE1 knockin induces systemic diabetes in mice. Diabetologia. 2016;59(7):1513–1523. doi: 10.1007/s00125-016-3960-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Prokopenko et al. (2021).Prokopenko D, Morgan SL, Mullin K, Hofmann O, Chapman B, Kirchner R, Alzheimer’s Disease Neuroimaging Initiative. Amberkar S, Wohlers I, Lange C. Whole-genome sequencing reveals new Alzheimer’s disease–associated rare variants in loci related to synaptic function and neuronal development. Alzheimer’s & Dementia. 2021 doi: 10.1002/alz.12319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Rehiman et al. (2020b).Rehiman SH, Lim SM, Neoh CF, Majeed ABA, Chin A-V, Tan MP, Kamaruzzaman SB, Ramasamy K. Proteomics as a reliable approach for discovery of blood-based Alzheimer’s disease biomarkers: a systematic review and meta-analysis. Ageing Research Reviews. 2020b;60:101066. doi: 10.1016/j.arr.2020.101066. [DOI] [PubMed] [Google Scholar]
  • Reseco et al. (2021).Reseco L, Atienza M, Fernandez-Alvarez M, Carro E, Cantero JL. Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alzheimer’s Research & Therapy. 2021;13(1):1–12. doi: 10.1186/s13195-021-00891-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Rueli et al. (2017).Rueli RH, Torres DJ, Dewing AS, Kiyohara AC, Barayuga SM, Bellinger MT, Uyehara-Lock JH, White LR, Moreira PI, Berry MJ. Selenoprotein S reduces endoplasmic reticulum stress-induced phosphorylation of tau: potential role in selenate mitigation of tau pathology. Journal of Alzheimer’s Disease. 2017;55(2):749–762. doi: 10.3233/JAD-151208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Shah, Kishore & Shastri (2021).Shah A, Kishore U, Shastri A. Complement system in Alzheimer’s disease. International Journal of Molecular Sciences. 2021;22(24):13647. doi: 10.3390/ijms222413647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Shi et al. (2019a).Shi X, Ohta Y, Liu X, Shang J, Morihara R, Nakano Y, Feng T, Huang Y, Sato K, Takemoto M. Acute anti-inflammatory markers ITIH4 and AHSG in mice brain of a novel Alzheimer’s disease model. Journal of Alzheimer’s Disease. 2019a;68(4):1667–1675. doi: 10.3233/JAD-181218. [DOI] [PubMed] [Google Scholar]
  • Shi et al. (2019b).Shi X, Ohta Y, Liu X, Shang J, Morihara R, Nakano Y, Feng T, Huang Y, Sato K, Takemoto M. Chronic cerebral hypoperfusion activates the coagulation and complement cascades in Alzheimer’s Disease mice. Neuroscience. 2019b;416(Suppl 1):126–136. doi: 10.1016/j.neuroscience.2019.07.050. [DOI] [PubMed] [Google Scholar]
  • Smith et al. (2011).Smith ER, Nilforooshan R, Weaving G, Tabet N. Plasma fetuin-A is associated with the severity of cognitive impairment in mild-to-moderate Alzheimer’s disease. Journal of Alzheimer’s Disease. 2011;24(2):327–333. doi: 10.3233/JAD-2011-101872. [DOI] [PubMed] [Google Scholar]
  • Solovyev (2020).Solovyev N. Selenoprotein P and its potential role in Alzheimer’s disease. Hormones. 2020;19(1):73–79. doi: 10.1007/s42000-019-00112-w. [DOI] [PubMed] [Google Scholar]
  • Song et al. (2014).Song F, Poljak A, Kochan NA, Raftery M, Brodaty H, Smythe GA, Sachdev PS. Plasma protein profiling of mild cognitive impairment and Alzheimer’s disease using iTRAQ quantitative proteomics. Proteome Science. 2014;12(1):1–13. doi: 10.1186/1477-5956-12-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Srinivasan et al. (2020).Srinivasan K, Friedman BA, Etxeberria A, Huntley MA, van Der Brug MP, Foreman O, Paw JS, Modrusan Z, Beach TG, Serrano GE. Alzheimer’s patient microglia exhibit enhanced aging and unique transcriptional activation. Cell Reports. 2020;31(13):107843. doi: 10.1016/j.celrep.2020.107843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Suidan et al. (2018).Suidan GL, Singh PK, Patel-Hett S, Chen Z-L, Volfson D, Yamamoto-Imoto H, Norris EH, Bell RD, Strickland S. Abnormal clotting of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability. Blood Advances. 2018;2(9):954–963. doi: 10.1182/bloodadvances.2018017798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Tenner (2020).Tenner AJ. Complement-mediated events in Alzheimer’s disease: mechanisms and potential therapeutic targets. The Journal of Immunology. 2020;204:306–315. doi: 10.4049/jimmunol.1901068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Vowinkel et al. (2004).Vowinkel T, Mori M, Krieglstein CF, Russell J, Saijo F, Bharwani S, Turnage RH, Davidson WS, Tso P, Granger DN. Apolipoprotein A-IV inhibits experimental colitis. The Journal of Clinical Investigation. 2004;114:260–269. doi: 10.1172/JCI21233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wright & Harding (2015).Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. Journal of Alzheimer’s Disease. 2015;45(4):985–1000. doi: 10.3233/JAD-142814. [DOI] [PubMed] [Google Scholar]
  • Yang et al. (2012).Yang M-H, Yang Y-H, Lu C-Y, Jong S-B, Chen L-J, Lin Y-F, Wu S-J, Chu P-Y, Chung T-W, Tyan Y-C. Activity-dependent neuroprotector homeobox protein: a candidate protein identified in serum as diagnostic biomarker for Alzheimer’s disease. Journal of Proteomics. 2012;75(12):3617–3629. doi: 10.1016/j.jprot.2012.04.017. [DOI] [PubMed] [Google Scholar]
  • Zhang & Song (2021).Zhang Z-H, Song G-L. Roles of selenoproteins in brain function and the potential mechanism of selenium in Alzheimer’s disease. Frontiers in Neuroscience. 2021;15:215. doi: 10.3389/fnins.2021.646518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Zhang et al. (2003).Zhang P, Yang Z, Zhang C, Lu Z, Shi X, Zheng W, Wan C, Zhang D, Zheng C, Li S. Association study between late-onset Alzheimer’s disease and the transferrin gene polymorphisms in Chinese. Neuroscience Letters. 2003;349(3):209–211. doi: 10.1016/S0304-3940(03)00837-1. [DOI] [PubMed] [Google Scholar]
  • Zhu et al. (2018).Zhu Y, Hilal S, Chai YL, Ikram MK, Venketasubramanian N, Chen CP, Lai MK. Serum hepatocyte growth factor is associated with small vessel disease in Alzheimer’s dementia. Frontiers in Aging Neuroscience. 2018;10:8. doi: 10.3389/fnagi.2018.00008. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Information 1. Significant KEGG pathways and GO terms enriched for CADvC and MADvC.
peerj-12-17643-s001.docx (24.4KB, docx)
DOI: 10.7717/peerj.17643/supp-1
Supplemental Information 2. Forest plots for abundance levels of the dysregulated proteins identified in CADvC among groups of AD patient vs normal control.

Note: Blue dot (Hedges’ g) represents the SMD for each individual study where the positive value indicates higher levels of proteins in AD compared to normal controls. Green dot indicates the total SMD controlled by the combined effects of prediction interval (PI) and confidence interval (CI). Total SMD with positive value indicates upregulation of the proteins in AD group.

peerj-12-17643-s002.docx (139.9KB, docx)
DOI: 10.7717/peerj.17643/supp-2
Supplemental Information 3. Forest plots for abundance levels of the dysregulated proteins identified in MADvC among groups of AD patient vs normal controls.

Note: Blue dot (Hedges’ g) represents the SMD for each individual study where the positive value indicates higher levels of proteins in AD compared to normal controls. Green dot indicates the total SMD controlled by the combined effects of prediction interval (PI) and confidence interval (CI). Total SMD with positive value indicates upregulation of the proteins in AD group.

peerj-12-17643-s003.docx (61.5KB, docx)
DOI: 10.7717/peerj.17643/supp-3
Supplemental Information 4
peerj-12-17643-s004.docx (38.4KB, docx)
DOI: 10.7717/peerj.17643/supp-4
Supplemental Information 5
peerj-12-17643-s005.docx (27.2KB, docx)
DOI: 10.7717/peerj.17643/supp-5
Supplemental Information 6. Supplementary Methods.
peerj-12-17643-s006.docx (20.5KB, docx)
DOI: 10.7717/peerj.17643/supp-6
Supplemental Information 7. The full version of HC using 163 proteins.
DOI: 10.7717/peerj.17643/supp-7
Supplemental Information 8. Sociodemographic, lifestyle and physical questionnaire.
peerj-12-17643-s008.docx (37.4KB, docx)
DOI: 10.7717/peerj.17643/supp-8
Supplemental Information 9. Dataset for survey analysis.
peerj-12-17643-s009.xlsx (16.9KB, xlsx)
DOI: 10.7717/peerj.17643/supp-9
Supplemental Information 10. STROBE checklist.
peerj-12-17643-s010.doc (81.5KB, doc)
DOI: 10.7717/peerj.17643/supp-10

Data Availability Statement

The following information was supplied regarding data availability:

The mass spectrometry proteomics data are available at the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository: PXD040566.

The raw data for the survey analysis is available in the Supplemental File.


Articles from PeerJ are provided here courtesy of PeerJ, Inc

RESOURCES